How did GLYC's revenue and expenses shift in Q4 2024?
5/8/2025 02:11pm
Aime
Glycomimetics (GLYC) experienced a significant shift in its financial metrics during Q4 2024, with total revenue decreasing, while cost of goods sold, R&D expenses, and sales and marketing expenses increased compared to the previous quarter1:
GLYC R&D Expenses
Source:
1.
GLYC Revenue, Cost of Sales, R&D Expenses, Sales and Marketing Expenses, Financial Expenses in Q4 2024
more
less
Explore
Screener
What are the best stocks to buy now?
Analysis
Aple Rating chart
Learn
Advanced technical indicators and how they are calculated and utilized